Brentuximab vedotin (BV), an anti-CD30 antibody-conjugated monomethyl auristatin E (MMAE), monotherapy has demonstrated high clinical efficacy as a salvage therapy for relapsed anaplastic large cell lymphoma (ALCL) [3,4]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.